Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760908566> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2760908566 endingPage "TPS10587" @default.
- W2760908566 startingPage "TPS10587" @default.
- W2760908566 abstract "TPS10587 Background: Tazemetostat is a potent and selective inhibitor of the histone methyltransferase enhancer of zeste-homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2). EZH2 is responsible for trimethylation of lysine 27 on histone H3, which results in chromatin remodelling and repressed transcription. Aberrant EZH2 activity has been implicated as an oncogenic driver in non-Hodgkin lymphoma and other malignancies. The SWI/SNF complex also remodels chromatin, activates transcription, and acts in opposition to PRC2. Oncogenesis from mutation and/or loss of the SWI/SNF subunit INI1 in cancers such as malignant rhabdoid tumor (MRT) or SMARCA4 loss in ovarian “small cell carcinoma, hypercalcemic type” is associated with anticancer activity of EZH2 inhibition in preclinical models. This has translated into objective responses of promising durability in subjects (subjs) whose solid tumors exhibited either INI1 or SMARCA4 loss in the tazemetostat phase I adult study. Methods: This phase I, multi-center dose escalation (DEsc) and dose expansion (DExp) study administers tazemetostat twice daily (BID) using an oral suspension formulation in pediatric subjs age 6 months to 21 years. Approximately 24 subjs will be dosed using a “Rolling 6” DEsc design at a starting dose of 240 mg/m2 BID. Following DEsc, a DExp cohort will enroll up to 20 subjs. Eligible malignancies includerhabdoid tumors (MRT, atypical teratoid rhabdoid tumor, rhabdoid tumor of the kidney, MRT of ovary) that are INI1 or SMARCA4 negative, synovial sarcoma, and other INI1 negative tumors including epithelioid sarcoma, renal medullary carcinoma, myoepithelial carcinoma, and others. Response assessments are evaluated every 8 weeks using RANO or RECIST 1.1. Primary endpoints include dose-limiting toxicities/maximum tolerated dose (DEsc) and overall response rate (ORR) (DExp). Secondary endpoints include ORR (DEsc), progression-free survival, overall survival, safety/tolerability, PK and duration of response for confirmed responders. The first subj was dosed in January 2016 in the US with additional sites to be opened in Canada, the EU and Australia (NCT02601937). Clinical trial information: NCT02601937." @default.
- W2760908566 created "2017-10-20" @default.
- W2760908566 creator A5001861945 @default.
- W2760908566 creator A5007441008 @default.
- W2760908566 creator A5009761094 @default.
- W2760908566 creator A5033018791 @default.
- W2760908566 creator A5040949476 @default.
- W2760908566 creator A5045714647 @default.
- W2760908566 creator A5061278042 @default.
- W2760908566 creator A5072295910 @default.
- W2760908566 creator A5081151795 @default.
- W2760908566 creator A5084587717 @default.
- W2760908566 creator A5086652615 @default.
- W2760908566 date "2016-05-20" @default.
- W2760908566 modified "2023-10-17" @default.
- W2760908566 title "A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma." @default.
- W2760908566 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.tps10587" @default.
- W2760908566 hasPublicationYear "2016" @default.
- W2760908566 type Work @default.
- W2760908566 sameAs 2760908566 @default.
- W2760908566 citedByCount "5" @default.
- W2760908566 countsByYear W27609085662018 @default.
- W2760908566 countsByYear W27609085662019 @default.
- W2760908566 countsByYear W27609085662021 @default.
- W2760908566 crossrefType "journal-article" @default.
- W2760908566 hasAuthorship W2760908566A5001861945 @default.
- W2760908566 hasAuthorship W2760908566A5007441008 @default.
- W2760908566 hasAuthorship W2760908566A5009761094 @default.
- W2760908566 hasAuthorship W2760908566A5033018791 @default.
- W2760908566 hasAuthorship W2760908566A5040949476 @default.
- W2760908566 hasAuthorship W2760908566A5045714647 @default.
- W2760908566 hasAuthorship W2760908566A5061278042 @default.
- W2760908566 hasAuthorship W2760908566A5072295910 @default.
- W2760908566 hasAuthorship W2760908566A5081151795 @default.
- W2760908566 hasAuthorship W2760908566A5084587717 @default.
- W2760908566 hasAuthorship W2760908566A5086652615 @default.
- W2760908566 hasConcept C126322002 @default.
- W2760908566 hasConcept C142724271 @default.
- W2760908566 hasConcept C143998085 @default.
- W2760908566 hasConcept C167227067 @default.
- W2760908566 hasConcept C177450382 @default.
- W2760908566 hasConcept C2776910622 @default.
- W2760908566 hasConcept C2778256501 @default.
- W2760908566 hasConcept C2781113665 @default.
- W2760908566 hasConcept C50171091 @default.
- W2760908566 hasConcept C502942594 @default.
- W2760908566 hasConcept C54355233 @default.
- W2760908566 hasConcept C552990157 @default.
- W2760908566 hasConcept C71924100 @default.
- W2760908566 hasConcept C80828422 @default.
- W2760908566 hasConcept C83640560 @default.
- W2760908566 hasConcept C86803240 @default.
- W2760908566 hasConceptScore W2760908566C126322002 @default.
- W2760908566 hasConceptScore W2760908566C142724271 @default.
- W2760908566 hasConceptScore W2760908566C143998085 @default.
- W2760908566 hasConceptScore W2760908566C167227067 @default.
- W2760908566 hasConceptScore W2760908566C177450382 @default.
- W2760908566 hasConceptScore W2760908566C2776910622 @default.
- W2760908566 hasConceptScore W2760908566C2778256501 @default.
- W2760908566 hasConceptScore W2760908566C2781113665 @default.
- W2760908566 hasConceptScore W2760908566C50171091 @default.
- W2760908566 hasConceptScore W2760908566C502942594 @default.
- W2760908566 hasConceptScore W2760908566C54355233 @default.
- W2760908566 hasConceptScore W2760908566C552990157 @default.
- W2760908566 hasConceptScore W2760908566C71924100 @default.
- W2760908566 hasConceptScore W2760908566C80828422 @default.
- W2760908566 hasConceptScore W2760908566C83640560 @default.
- W2760908566 hasConceptScore W2760908566C86803240 @default.
- W2760908566 hasIssue "15_suppl" @default.
- W2760908566 hasLocation W27609085661 @default.
- W2760908566 hasOpenAccess W2760908566 @default.
- W2760908566 hasPrimaryLocation W27609085661 @default.
- W2760908566 hasRelatedWork W2074694159 @default.
- W2760908566 hasRelatedWork W2158490603 @default.
- W2760908566 hasRelatedWork W2575583123 @default.
- W2760908566 hasRelatedWork W2603189030 @default.
- W2760908566 hasRelatedWork W2767008663 @default.
- W2760908566 hasRelatedWork W2781962409 @default.
- W2760908566 hasRelatedWork W2790981342 @default.
- W2760908566 hasRelatedWork W3014321958 @default.
- W2760908566 hasRelatedWork W3033232203 @default.
- W2760908566 hasRelatedWork W3136392956 @default.
- W2760908566 hasVolume "34" @default.
- W2760908566 isParatext "false" @default.
- W2760908566 isRetracted "false" @default.
- W2760908566 magId "2760908566" @default.
- W2760908566 workType "article" @default.